LEAMINGTON, ON, April 18, 2019 /PRNewswire/ – Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA and NYSE: APHA) today announced that its German subsidiary Aphria Deutschland GmbH (“Aphria Germany“) has secured the previously announced license for the domestic cultivation of medical cannabis from the German Federal Institute for Drugs and Medical Devices (“BfArM“), following the conclusion of a mandatory 10-day standstill period for public contracts. Aphria was granted a cultivation license for four of the nine total lots awarded by BfArM and is awaiting the completion of the tender process for the four remaining lots under review, one of which was provisionally awarded to Aphria Germany.
“Aphria thanks the BfArM for their diligent examination and validation of our approach for domestic cultivation with this license,” said Hendrik Knopp, Managing Director of Aphria Germany. “Construction on our 8,000 square meter indoor cultivation facility is already underway and we anticipate it will be fully operational by Summer 2020. We are pleased to additionally support German patients in the upcoming months with high-quality imported cannabis flower and oils from Denmark and Canada.”
Aphria Germany is building its indoor growing facility in Neumünster and is completing work on a state-of-the-art GMP-certified cannabis vault in Bad Bramstedt for the import of cannabis flowers and oil from Canada and Denmark. Aphria Germany also holds a 25.1% interest in Berlin-based Schöneberg Hospital, which provides access to both doctors and patients for education on the benefits of medical cannabinoids. Earlier this month, the company launched CannRelief, a CBD-based nutraceutical and cosmetics product line for the German market, produced in the EU and distributed by CC Pharma, a subsidiary of Aphria Inc. with access to more than 13,000 pharmacies throughout Germany.
We Have A Good Thing Growing
About Aphria
Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.
For more information, visit: aphria.ca
Source: Aphria Inc.
Read more APHA news & articles
Aphria Inc. (TSX: APHA) 6 Month Chart
Create your own APHA technical and interactive chart – Barchart
Aphria Inc. (TSX: APHA) Technical Analysis Signal
Continue Reading
Read all our featured articles here
Read Cannabis industry articles here
Read Technical Analysis articles here
Watch Cannabis stock videos here
The Cannabis Investor is a leading media outlet for Cannabis investment opportunities and breaking industry news. TCI is focused on uncovering paradigm-shifting marijuana stocks and reporting on the evolving cannabis value chain.
Join our text message list:
USA: Text potstocks to 313131 to join
CDN: Text potstocks to 393939 to join
Join our email list here: https://www.thecannabisinvestor.ca/newsletter-sign-up/
Follow The Cannabis Investor on Social Media
Facebook: https://www.facebook.com/MMJInvestor
Instagram: https://www.instagram.com/thecannabisinvestor/
Twitter: https://twitter.com/MJStockNews
LinkedIn: https://www.linkedin.com/company/the-cannabis-investor/